223 related articles for article (PubMed ID: 30795731)
1. Safety of tiotropium in patients with asthma.
Dusser D; Ducharme FM
Ther Adv Respir Dis; 2019; 13():1753466618824010. PubMed ID: 30795731
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
[TBL] [Abstract][Full Text] [Related]
3. Tiotropium for the treatment of asthma: a drug safety evaluation.
Kerstjens HA; O'Byrne PM
Expert Opin Drug Saf; 2016 Aug; 15(8):1115-24. PubMed ID: 27279414
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.
Vogelberg C; Engel M; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Downie J; Nething K; Vevere V; Vandewalker M
Respir Med; 2014 Sep; 108(9):1268-76. PubMed ID: 25081651
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
6. A comparison of tiotropium, long-acting β
Vogelberg C; Goldstein S; Graham L; Kaplan A; de la Hoz A; Hamelmann E
Respir Res; 2020 Jan; 21(1):19. PubMed ID: 31931792
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.
Vogelberg C; Szefler SJ; Vrijlandt EJLE; Boner AL; Engel M; El Azzi G; Vulcu SD; Moroni-Zentgraf PM; Eickmeier O; Hamelmann EH
Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 31097514
[TBL] [Abstract][Full Text] [Related]
8. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
[TBL] [Abstract][Full Text] [Related]
9. Safety of tiotropium Respimat
Graham LM; Kerstjens HAM; Vogelberg C; Hamelmann E; Szefler SJ; Pisternick-Ruf W; Engel M; El Azzi G; Unseld A; Foggs MB
Respir Med; 2019 Aug; 155():58-60. PubMed ID: 31302579
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium for the treatment of asthma in adolescents.
Hamelmann E; Vogelberg C; Szefler SJ
Expert Opin Pharmacother; 2017 Feb; 18(3):305-312. PubMed ID: 28110558
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E
J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670
[TBL] [Abstract][Full Text] [Related]
12. Burden of Asthma and Role of 2.5 µg Tiotropium Respimat
Mansfield L; Duong-Quy S; Craig T
Adv Ther; 2019 Oct; 36(10):2587-2599. PubMed ID: 31435830
[TBL] [Abstract][Full Text] [Related]
13. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
Halpin DM; Kaplan AG; Russell RK
Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis.
Wang L; Zhou R; Xie X
J Asthma; 2019 Jan; 56(1):69-78. PubMed ID: 29420077
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium in children and adolescents with asthma.
Murphy KR; Chipps BE
Ann Allergy Asthma Immunol; 2020 Mar; 124(3):267-276.e3. PubMed ID: 31805357
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium in the add-on treatment of asthma in adults: clinical trial evidence and experience.
Vogelberg C
Ther Adv Respir Dis; 2016 Dec; 10(6):525-533. PubMed ID: 27612491
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.
Hamelmann E; Bernstein JA; Vandewalker M; Moroni-Zentgraf P; Verri D; Unseld A; Engel M; Boner AL
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 27811070
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium in asthma: From bench to bedside.
Mansfield L; Bernstein JA
Respir Med; 2019; 154():47-55. PubMed ID: 31212121
[TBL] [Abstract][Full Text] [Related]
19. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
[TBL] [Abstract][Full Text] [Related]
20. Asthma exacerbations and worsenings in patients aged 1-75 years with add-on tiotropium treatment.
Mark FitzGerald J; Hamelmann E; Kerstjens HAM; Buhl R
NPJ Prim Care Respir Med; 2020 Aug; 30(1):38. PubMed ID: 32868782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
